Back to Journals » Lung Cancer: Targets and Therapy » Volume 7

HSP90 as a novel molecular target in non-small-cell lung cancer

Authors Esfahani K, Cohen V

Received 9 October 2015

Accepted for publication 20 November 2015

Published 1 March 2016 Volume 2016:7 Pages 11—17

DOI https://doi.org/10.2147/LCTT.S60344

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Pan-Chyr Yang


Khashayar Esfahani, Victor Cohen

Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada

Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.

Keywords: non-small-cell lung cancer, driver mutations, targeted therapy, heat shock protein 90 (HSP90)

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]